ArticleJournal of blood medicine2013

Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.

Violaine Havelange et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.